Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBanco Santander Regulatory News (BNC)

Share Price Information for Banco Santander (BNC)

Share Price is delayed by 15 minutes
Get Live Data
1,020.00    0.00 (0.00%)
Bid:
1,030.00
Ask:
1,036.00
Spread: 6.00 (0.583%)
Market Cap: £146.15b
BNC Live PriceLast checked at - London Stock Exchange

Intraday Banco Santander Share Chart

Invitation to purchase certain instruments

13 Feb 2025 12:00

RNS Number : 0545X
Banco Santander S.A.
13 February 2025
 

Banco Santander, S.A., ("Santander" or the "Offeror") in accordance with the provisions of the securities market legislation, communicates the following:

OTHER RELEVANT INFORMATION

Further to the communication made on 6 February 2025 (registered under number 2585) regarding the invitation by Santander to holders of its outstanding €1,500,000,000 3.250 per cent. Subordinated Instruments due April 2026 (ISIN: XS1384064587) (the "EUR 2026 Notes") and €1,000,000,000 3.125 per cent. Subordinated Instruments due January 2027 (ISIN: XS1548444816) (the "EUR 2027 Notes" and, together with the EUR 2026 Notes, the "Notes" and each a "Series") to tender any and all of such Notes for purchase by the Offeror for cash, in accordance with the terms of the tender offer memorandum dated 6 February 2025 (the "Tender Offer Memorandum") (the "Offers"), the Offeror now announces the results of the Offers.

Capitalised terms used but not otherwise defined in this announcement shall have the meaning given to them in the Tender Offer Memorandum.

The Expiration Time for the Offers was 5.00 p.m. (CET) on 12 February 2025.

The Offeror hereby announces that it will accept for purchase in accordance with the terms and subject to the conditions set out in the Tender Offer Memorandum and at the relevant Purchase Price: (i) €600,800,000 in aggregate principal amount of the EUR 2026 Notes; and (ii) €563,600,000 in aggregate principal amount of the EUR 2027 Notes, as set out in the table below.

 

Description of Notes

ISIN

Maturity Date

Aggregate principal amount accepted

Reference Benchmark

Reference Benchmark Yield

Purchase Spread

Purchase Yield

Purchase Price (expressed as a percentage)

€1,500,000,000 3.250 per cent. Subordinated Instruments due April 2026

XS1384064587

4 April 2026

€600,800,000

EUR 2026 Interpolated Mid-Swap Rate

2.356%

+25 bps.

 

2.606%

100.701%

€1,000,000,000 3.125 per cent. Subordinated Instruments due January 2026

XS1548444816

19 January 2027

€563,600,000

EUR 2027 Interpolated Mid-Swap Rate

2.284%

+35 bps.

 

2.634%

100.905%

Notes purchased by the Offeror pursuant to the Offer will be cancelled by the Offeror and will not be re-issued or re-sold. Notes which have not been validly submitted or validly submitted but not accepted for purchase pursuant to the Offer will remain outstanding. Following the Settlement Date, there will be an outstanding nominal amount of (i) €899,200,000 of EUR 2026 Notes and (ii) €463,400,000 of EUR 2027 Notes.

Payment of the relevant Tender Consideration in respect of the Notes accepted for purchase by the Offeror will occur on the Settlement Date, which is expected to be 17 February 2025.

Any requests for information in relation to the Offers should be directed to the Dealer Managers or the Tender Agent whose contact details are listed below.

SOLE DEALER MANAGER

Santander Corporate and Investment Banking Ciudad Grupo SantanderAvenida de Cantabria s/n28660Madrid, SpainAttn: Liability ManagementEmail: liabilitymanagement@gruposantander.com

 

THE TENDER AGENTKroll Issuer Services Limited The Shard32 London Bridge StreetLondon SE1 9SGUnited KingdomTel: +44 20 7704 0880 Attn: David Shilson/Scott BoswellEmail: santander@is.kroll.comWebsite: https://deals.is.kroll.com/santander

 

 

Boadilla del Monte (Madrid), 13 February 2025

 

 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO OR TO ANY PERSON LOCATED OR RESIDENT IN ANY JURISDICTION WHERE OR TO WHOM IT IS UNLAWFUL TO RELEASE, PUBLISH OR DISTRIBUTE THIS ANNOUNCEMENT.

 

 

DISCLAIMER

This announcement must be read in conjunction with the Tender Offer Memorandum. This announcement and the Tender Offer Memorandum contain important information which should be read carefully before any decision is made with respect to the Offer. If any Qualifying Holder is in any doubt as to the contents of this announcement, the Tender Offer Memorandum or the action it should take, it is recommended to seek its own financial, legal, regulatory and tax advice, including in respect of any tax consequences, immediately from its broker, bank manager, solicitor, accountant or other independent financial, tax or legal adviser.

The distribution of this announcement and the Tender Offer Memorandum in certain jurisdictions may be restricted by law. Persons into whose possession this announcement and/or the Tender Offer Memorandum comes are required by each of the Offeror, the Sole Dealer Manager and the Tender Agent to inform themselves about, and to observe, any such restrictions.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
FURPKNBPDBKDOBD
Date   Source Headline
21st Feb 20243:33 pmRNSDirector/PDMR Shareholding
20th Feb 20247:00 amRNSNotice of AGM
19th Feb 202411:17 amRNSDividend approval & buyback program implementation
19th Feb 20247:45 amRNSFurther re dividend approval
19th Feb 20247:43 amRNSDividend approval & buyback program implementation
7th Feb 20244:39 pmRNSDirector/PDMR Shareholding
7th Feb 20244:38 pmRNSDirector/PDMR Shareholding
7th Feb 20244:36 pmRNSDirector/PDMR Shareholding
5th Feb 20245:48 pmRNSFurther re capital reduction
1st Feb 20244:46 pmRNSDirector/PDMR Shareholding
31st Jan 20243:55 pmRNSTotal Voting Rights
31st Jan 20247:00 amRNS2023 Results - Press release
31st Jan 20247:00 amRNS2023 Results Report & Earnings Presentation
26th Jan 202411:32 amRNSCapital reduction following completion of program
26th Jan 202411:19 amRNSTransaction in Own Shares
24th Jan 202411:06 amRNSNotice of 2023 Results Presentation
18th Jan 202411:05 amRNSBuyback programme: transactions 11-17 Jan
11th Jan 202411:08 amRNSBuyback programme: transactions 4-10 Jan
4th Jan 202411:07 amRNSBuyback programme: transactions 28 Dec- 3 Jan
29th Dec 202311:58 amRNSTotal Voting Rights
28th Dec 202311:08 amRNSBuyback programme: transactions 21-27 Dec
21st Dec 202311:07 amRNSBuyback programme: transactions 14-20 Dec
20th Dec 20234:14 pmRNSDirector/PDMR Shareholding
20th Dec 20237:00 amRNSAdapting reporting to new operating model (ppt)
20th Dec 20237:00 amRNSAdapting reporting to new operating model (PR)
18th Dec 20235:22 pmRNSDirector/PDMR Shareholding
18th Dec 20235:17 pmRNSDirector/PDMR Shareholding
18th Dec 20237:05 amRNSDirector/PDMR Shareholding
14th Dec 202311:05 amRNSBuyback programme: transactions 5-13 Dec
13th Dec 20234:41 pmRNSDirector/PDMR Shareholding
13th Dec 20237:02 amRNSOptional early redemption ISIN XS1951093894
11th Dec 202311:24 amRNSSREP Capital Requirements 2024
5th Dec 202311:09 amRNSBuyback programme: transactions 30 Nov – 4 Dec
30th Nov 202311:18 amRNSTotal Voting Rights
30th Nov 202311:12 amRNSBuyback programme: transactions 23-29 Nov
23rd Nov 202311:07 amRNSBuyback programme: transactions 16-22 Nov
22nd Nov 20237:08 amRNSOptional early redemption ISIN XS1692931121
17th Nov 20237:00 amRNSAT1s Contingent Convertible securities
16th Nov 20232:24 pmRNSBuyback programme: transactions 8-15 Nov
16th Nov 202311:06 amRNSBuyback programme: transactions 8-15 Nov
8th Nov 202311:06 amRNSBuyback programme: transactions 31 Oct – 7 Nov
31st Oct 202312:03 pmRNSTotal Voting Rights
31st Oct 202310:14 amRNSBuyback programme: transactions 26–30 Oct
26th Oct 202312:09 pmRNSTotal Voting Rights
26th Oct 202311:05 amRNSBuyback programme: transactions 19 Oct – 25 Oct
25th Oct 20237:00 amRNS3Q 2023 Results Report & Earnings Presentation
25th Oct 20237:00 amRNS3rd Quarter 2023 Results - Press release
19th Oct 202311:08 amRNSBuyback programme: transactions 11 Oct – 18 Oct
18th Oct 202311:11 amRNSNotice of Third Quarter 2023 Results
11th Oct 202311:27 amRNSBuyback programme: transactions 5 Oct – 10 Oct

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.